Jonah Feldman

A combination regimen targeting LAG-3 and PD-1 did not significantly extend progression-free survival in advanced melanoma vs single-agent pembrolizumab.

Izalontamab brengitecan achieved dual primary end point improvements in PFS and OS versus physician’s choice chemotherapy in previously treated locally advanced/metastatic TNBC, challenging later-line single-agent chemotherapy standards.

Targeting KMA seeks to spare normal immunoglobulin-producing plasma cells, differentiating from BCMA-directed CAR T approaches associated with broader plasma-cell depletion and infectious complications. KOALA is a single-center phase 1 dose-escalation trial assessing safety and preliminary efficacy, with ~12 patients and primary completion projected for September 2028.

In an in-depth interview, Omar Nadeem, MD, explores the promising findings from 20 patients with smoldering myeloma treated with cilta-cel.

Belantamab mafodotin plus triplet induction and maintenance yields responses in transplant-ineligible newly diagnosed multiple myeloma population.

Blenrep produced strong responses and manageable side effects in transplant-ineligible patients with newly diagnosed multiple myeloma.

The AKT inhibitor ipatasertib resulted in 41% overall response rate when combined with pembrolizumab in head and neck squamous cell carcinoma.

A PD-1/TIGIT bispecific antibody plus T-DXd yielded pathologic complete responses, avoiding need for further chemotherapy.

Tucatinib plus trastuzumab/pertuzumab continued to show benefit in patients with HER2+ breast cancer regardless of distinguishing disease features.

Findings from the I-SPY 2.2 trial may show an important step toward treatment de-escalation for certain patients with HER2-negative breast cancer.